After 18 months of productive collaborative work between regional biotech startup GenTech Analytica and Bermuda-headquartered genomics leader CariGenetics, the Caribbean-based research and innovation hub has formally rebranded as CariGenetics Saint Lucia — a milestone that marks a major leap forward for homegrown genomics, precision medicine and public health innovation across Saint Lucia and the entire Organisation of Eastern Caribbean States (OECS) region.
CariGenetics, the parent organization, has long centered its mission on closing critical global gaps in genomic data by sequencing and studying genetic material from Caribbean populations, groups that have historically been drastically underrepresented in international genomic research. Through targeted research, community-focused education and expanded access to precision medicine tools, the organization works to directly improve health outcomes for communities across the Caribbean region.
The 18-month partnership between the two entities has already delivered tangible impact for local communities. Teams launched Saint Lucia’s first-ever population-based prostate cancer genetic study, and brought accessible genetic testing services to the region, giving thousands of local residents access to personalized health insights that were previously out of reach. Beyond direct services, the collaboration also expanded outreach efforts to boost public literacy around genetics and deepen regional engagement with genomic health initiatives.
The unification of the two operations under a single shared brand does more than streamline operations: it consolidates scattered Caribbean genetic research efforts under a regional identity, strengthening collective voice and impact. Leadership from the newly branded entity has already presented key genomic and population health findings to OECS governing bodies, outlining how genetic insights can drive more targeted public health action for high-priority concerns including cancer, non-communicable diseases (NCDs), medication safety, and long-term regional health planning. The team has also put forward actionable frameworks for integrating genomics into existing regional health systems in a way that centers local needs and upholds ethical data practices.
This formal expansion significantly boosts CariGenetics’ overall capacity to support regional governments, healthcare providers, academic research partners and local communities. It combines coordinated global research infrastructure with an embedded, experienced local team across the OECS, equipping stakeholders with practical, evidence-based tools to shape disease prevention strategies, guide clinical treatment decisions, and inform public health policy.
Dr. Carika Weldon, founder and Chief Executive Officer of CariGenetics, emphasized that the rebranding is far more than a corporate rebranding exercise — it is a reflection of the organization’s core commitment to building indigenous scientific capacity across the Caribbean, while keeping local communities at the center of every stage of genomic innovation.
“This is about more than business growth. It is about building the infrastructure, trust, and partnerships needed to ensure Caribbean people are represented in the future of precision medicine with excellent local talent,” Weldon explained. “Through CariGenetics Saint Lucia, we are strengthening our ability to work alongside local and regional partners to advance research, improve education and support more personalised approaches to healthcare for our communities.”
For the original GenTech Analytica team, the transition opens a new chapter for a vision that launched just two years ago: to guarantee the Caribbean a seat at the table in the future of global genetics and precision medicine. From its origins as an early-stage entrepreneurial concept, GenTech Analytica grew into a robust platform that connects scientific communication, cross-regional engagement, and community-focused health innovation.
Devy Frederick, founder of GenTech Analytica and newly appointed Chief Executive Officer of CariGenetics Saint Lucia, called the milestone a profound moment of pride for the regional startup community. “GenTech Analytica started with the belief that the Caribbean should have a voice in the future of genetics and precision medicine,” Frederick said. “To see that vision now become CariGenetics Saint Lucia after two years is a proud moment. I hope this also encourages other young Caribbean entrepreneurs to take their ideas seriously, build partnerships, and create solutions that can contribute meaningfully to the development of our region.”
Looking forward, CariGenetics Saint Lucia will prioritize four core strategic goals: advancing indigenous Caribbean-led genomic research, expanding affordable access to genetic testing across the OECS, supporting clinical and public health decision-making, and building cross-sector partnerships to ensure Caribbean populations are fairly represented in global genomic science. Key priority areas of work include cancer genomics, consumer wellness genetic testing, pharmacogenomics, polygenic risk score development, and the creation of responsible, community-centered regulatory frameworks for genomic data stewardship.
Each of these areas plays a central role in the future of precision medicine. Pharmacogenomics, for example, maps how an individual’s genetic makeup influences their response to common medications, allowing clinicians to prescribe more effective, lower-risk treatment plans. Polygenic risk scores, meanwhile, give clinicians and public health planners insight into inherited disease risk patterns, enabling earlier screening, targeted prevention, and more proactive public health planning.
Regional health leaders note that this transition is more than a corporate milestone: it demonstrates a collective, shared commitment to positioning Caribbean communities not just as research participants in global genomics, but as leaders shaping how precision medicine is developed and delivered across the region. With the Caribbean facing one of the highest global burdens of non-communicable diseases, the localized genomic infrastructure built through CariGenetics Saint Lucia is poised to enable earlier disease identification, more accessible prevention services, and more effective personalized care for generations of Caribbean residents.